Endocrine Practice

Endocrine Practice (Endocr. Pract.) is an endocrinology journal published by Elsevier on behalf of the American Association of Clinical Endocrinology. Founded in 1995, it concentrates on clinical endocrinology including diabetes, thyroid disease, bone and metabolism, and on the association's guidelines, appears monthly, and had a 2025 impact factor of 4.4.《内分泌实践》（Endocrine Practice''''，缩写 Endocr. Pract.''）是爱思唯尔代表美国临床内分泌学会出版的内分泌学刊物，1995 年创刊。该刊以糖尿病、甲状腺、骨与代谢等内分泌临床议题及该会指南为主，现为月刊，二〇二五年影响因子为 4.4。

Scope

The journal's editorial stance is that a paper must serve clinical endocrine practice: however deep the mechanistic work, it has to yield actionable conclusions for the diagnosis, treatment or management of endocrine disease. Alongside research articles, the association's guidelines, consensus statements and care pathways are published here under double-blind review. Coverage includes:本刊的取稿立场是「面向内分泌科医师的临床实践」：一篇论文不论机制研究多么深入，都要对内分泌疾病的诊断、治疗或管理给出可操作的结论。除研究论文外，该会指南、共识声明与诊疗流程以双盲评审方式在本刊发表。收文方向包括：

• Diabetes and technology: glycaemic management, insulin and newer glucose-lowering agents, continuous glucose monitoring and insulin pumps, and prevention of diabetic complications.糖尿病与技术： 血糖管理方案、胰岛素与新型降糖药物、连续血糖监测与胰岛素泵、糖尿病并发症防治。

• Thyroid disease: thyroid dysfunction, thyroid nodules and thyroid cancer, thyroiditis, and thyroid disease in pregnancy.甲状腺疾病： 甲状腺功能异常、甲状腺结节与甲状腺癌、甲状腺炎、妊娠期甲状腺疾病。

• Bone and parathyroid: osteoporosis and fracture prevention, calcium and phosphate metabolism, parathyroid disorders, and bone turnover markers.骨与甲状旁腺： 骨质疏松与骨折预防、钙磷代谢、甲状旁腺功能异常、骨代谢标志物。

• Lipids and cardiovascular: management of dyslipidaemia, atherosclerotic cardiovascular risk, lipid-lowering therapy, and cardiovascular risk in endocrine disease.脂质与心血管： 血脂异常的管理、动脉粥样硬化性心血管病风险、降脂治疗、内分泌疾病的心血管风险。

• Pituitary and adrenal: pituitary disease, adrenal cortical and medullary disease, neuroendocrine tumours, and multiple endocrine neoplasia.垂体与肾上腺： 垂体疾病、肾上腺皮质与髓质疾病、神经内分泌肿瘤、多发性内分泌腺瘤病。

• Obesity and nutrition: assessment and treatment of obesity, weight-loss drugs and metabolic surgery, nutritional intervention, and gonadal and reproductive endocrinology.肥胖与营养： 肥胖的评估与治疗、减重药物与代谢手术、营养干预、性腺与生殖内分泌。

The journal is hybrid with an article processing charge of 3,850 US dollars. The publisher reports an official acceptance rate of 16 per cent, six days to first decision, thirty-one days to a decision after review, 75 days to acceptance and six days from acceptance to online publication, the first-decision figure including editorial screening.本刊为混合出版，文章处理费为三千八百五十美元；出版方公布官方录用比例为百分之十六、投稿至首次决定六天、复审后决定三十一天、投稿至接收七十五天、接收至上线六天，其中首次决定包含编辑部初筛。^[1]

History

• Founding (1995): the journal was founded in 1995 under its present name, with no predecessor title and no renaming. 2026 is volume 32, consistent with one volume a year创刊（1995年）： 1995 年创刊，创刊即使用现名，无前身刊名亦无改名；2026 年为第 32 卷，与一卷一期的编排相合；首任主编该会官方未列。 the association does not list the founding editor.

• Change of publisher (2021): from 1 January 2021 the journal has been published by Elsevier on behalf of the association. The association was formerly the American Association of Clinical Endocrinologists and took its present name in 2020.出版方变更（2021年）： 自 2021 年 1 月 1 日起，本刊由爱思唯尔代表该会出版；该会原名美国临床内分泌医师协会，2020 年更名为美国临床内分泌学会。^[2]

• Frequency and metrics: the journal appears monthly in one volume a year. The impact factor is 4.4 and the CiteScore 7.5, and the journal is indexed in Scopus, MEDLINE and the Science Citation Index Expanded.刊期与指标： 本刊为月刊，每年一卷；影响因子 4.4、引用分数 7.5；本刊被 Scopus、MEDLINE 与科学引文索引扩展版收录。^[1]

Editors

The editor is appointed by the association and the traceable succession begins in 2014. The present editor comes from Emory University and took up the post on 1 January 2021, coinciding with the transfer of publishing to Elsevier.本刊主编由该会任命，可考的历任自 2014 年起；现任主编来自埃默里大学，2021 年 1 月 1 日就任，与该刊转由爱思唯尔出版同步。^[2]

• Present editor-in-chief: Vin Tangpricha of the Division of Endocrinology, Metabolism and Lipids at Emory University School of Medicine took up the post on 1 January 2021.现任主编： （Vin Tangpricha）供职于埃默里大学医学院内分泌代谢与脂质科，2021 年 1 月 1 日就任。

• Predecessor: Derek LeRoith served from 2014 to 2020 and is the only predecessor documented by the association. During his tenure the journal moved from bimonthly to monthly and its impact factor rose from 2.58 in 2014 to 3.86 in 2020前任主编： （Derek LeRoith）2014 年至 2020 年在任，是该会官方可考的唯一一任前主编；任内本刊由双月刊升为月刊，影响因子由 2014 年的 2.58 升至 2020 年的 3.86；其余历任未公布。 the remaining incumbents are not published.

• Role in the field: the journal is the main publication channel for the association's guidelines and consensus statements, and its care pathway articles are widely used in endocrine practice in the United States. It also carries continuing education content for the association's members.学科角色： 本刊是该会指南与共识的主要发表渠道，其诊疗流程类文章在美国内分泌临床实践中被广泛采用；本刊也是该会会员继续教育内容的载体之一。